📋 FDA Reference

R2P Slenguide

Ashitaka Factory Of Terumo

Compare similar devices

Summary: The r2p slenguide is a guiding catheter used in endovascular procedures, particularly for venous stenting. It is typically used by interventional cardiologists and radiologists.

FDA Clearance Information

Pathway ? 510(k)
Number ? K161546 ↗
Decision Date ? October 14, 2016
Product Code ? DQY Catheter, Percutaneous
Device Class ? Class 2
Evidence ? 0 studies

The r2p slenguide was cleared through the FDA 510k pathway on October 14, 2016. It is manufactured by Ashitaka Factory Of Terumo and classified as a Class 2 device.

What It Is

The r2p slenguide is a guiding catheter designed for use in endovascular procedures. It features a long shaft and rapid-exchange system, which facilitates the placement of stents in peripheral arteries via transradial access. This design allows for improved maneuverability and access to difficult-to-reach vascular sites.

FDA-Cleared Indications

  • Used to provide a pathway for the introduction and guidance of interventional devices during percutaneous vascular procedures.
  • Used in endovascular procedures involving peripheral blood vessels when catheter guidance is required.
  • FDA-cleared under product code DQY, Catheter, Percutaneous, under 21 CFR 870.1250.

Clinical Applications

  • Guiding interventional devices during percutaneous peripheral vascular procedures.
  • Providing catheter support during endovascular treatment of peripheral vascular disease.
  • Facilitating delivery of a vascular stent when the anatomy and device compatibility are appropriate.
  • Use through transradial access when a suitable access sheath and catheter length are selected.

Reported off-label uses

  • Use as a guiding catheter for selected venous interventions, including venous stent delivery, when judged appropriate by the treating physician.
  • Use in other complex endovascular procedures requiring long catheter support or access to difficult vascular anatomy.

Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.

Practical Considerations

  • The provided product information describes compatibility with a 7-Fr Glidesheath Slender and use with a guiding catheter approximately 150 cm long; operators must confirm current manufacturer specifications before use.
  • Select the catheter size, length, guidewire and accessory devices according to the target vessel, access route and intended intervention.
  • Transradial use requires appropriate assessment of radial artery size, hand circulation and access-site risks.
  • MRI safety should not be assumed from the FDA clearance record. Confirm the current labeling for MR Safe, MR Conditional or MR Unsafe status before MRI.
  • Potential complications are those associated with percutaneous catheterization, including bleeding, hematoma, vessel injury, thrombosis, embolization, infection and contrast-related reactions.

Related Literature

The linked study reports the first human use of the R2P system, including the r2p slenguide, in a 73-year-old male with critical limb ischemia. The study demonstrated successful stenting of the left superficial femoral artery via radial access. Key findings include the device's effectiveness in transradial stenting, though the study is limited by its single-patient scope.

Procedures that use this device

Frequently Asked Questions

What is r2p slenguide used for?

The r2p slenguide is used for guiding stents in endovascular procedures, particularly in peripheral arteries.

What specialties typically use this device?

Interventional cardiologists and radiologists typically use this device.

What are the FDA-cleared indications?

The r2p slenguide is indicated for use in guiding stents to treat narrowed or blocked peripheral arteries.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you